Filter News

Egalet To Report First Quarter 2017 Financial Results During Investor Day On May 10, 2017 In New York

Published: Apr 26, 2017

WAYNE, Pa., April 26, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced it will host an investor event on Wednesday, May 10, 2017 in New York City, at which time the company will release its first quarter 2017 earnings results.

Egalet will moderate a discussion with leading healthcare providers who will discuss treating individuals living with pain in today's environment. Egalet management will provide an overview of the company's commercial, regulatory and business development activities, and review first quarter financial results.

Presentations will be webcast live starting at 12:45 p.m. EDT at http://egalet.investorroom.com/eventsandwebcasts.  A replay and transcript of the webcast will be available shortly after the event.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO ER (morphine sulfate) extended-release tablets for oral use only CII, developed using Egalet's proprietary Guardian Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only CII and SPRIX® (ketorolac tromethamine) Nasal Spray. Using Guardian Technology Egalet is developing a pipeline of clinical-stage, product candidates including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For full prescribing information on ARYMO ER, including the boxed warning and medication guide, please visit arymoer.com. For full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For full prescribing information on OXAYDO, including the boxed warning and medication guide, please visit oxaydo.com. For additional information on Egalet, please visit egalet.com.

Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/egalet-to-report-first-quarter-2017-financial-results-during-investor-day-on-may-10-2017-in-new-york-300445720.html

SOURCE Egalet Corporation

Back to news